Biotech startup developing longevity drugs for dogs #shorts

Summary

The discussion centers on a new preventative drug, analogous to statins, aimed at extending a dog's healthier lifespan by about a year through slowing the aging process. Silicon Valley is heavily investing in this longevity research, which is currently in clinical trials for dogs and shows promise for eventual application to human aging. The takeaway is that this approach focuses on adding healthy years by delaying decline, not on reviving individuals near death.